All In Biotech

Drug Trial Radar · NCT03483961

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)

Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 445 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

445

Actual

Start

Apr 18, 2018

Primary completion

Sep 14, 2020

Study completion Sep 21, 2020

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
Collaborators
Emergent BioSolutions
First posted
Mar 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults. Primary Objective: To assess the immune response to the vaccine Secondary Objectives: To assess the kinetics of the immune response to different doses/formulations/schedules To assess the persistence of immune responses to different doses/formulations/schedules To assess the effect of a booster dose of the vaccine Safety Objective: To assess local and systemic reactions to the vaccine and to describe the safety profile of the vaccine

Conditions

  • Chikungunya Virus Infection

Interventions

  • CHIKV VLP/unadjuvantedBiological

    Vaccine consists of virus-like particles of chikungunya virus antigens

  • CHIKV VLP/adjuvantedBiological

    Adjuvanted formulation includes Alhydrogel

  • PlaceboBiological

    Placebo is vaccine diluent alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.Time frame: Day 57 (from Day 1 vaccination), 28 days after the last injection.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Johnson County Clin-Trials

    Lenexa, Kansas

  • The Center for Pharmaceutical Research

    Kansas City, Missouri

  • Advanced Clinical Research

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.